At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 72 enrolled
Drug / intervention
pemetrexed disodium +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Phase II Study of Maintenance Pemetrexed Versus Observation for Patients With Malignant Pleural Mesothelioma Without Progression After First-Line Chemotherapy
In Brief
A Phase 2 clinical trial evaluating pemetrexed disodium and clinical observation for Malignant Mesothelioma. Completed, enrolled 72 participants across 145 sites.
Detailed Summary
RATIONALE: Pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This randomized phase II trial is studying how well pemetrexed disodium or observation works in treating patients with malignant pleural mesothelioma without progressive disease after first-line chemotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMalignant Mesothelioma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 2010
Enrollment StartApr 2010
Primary CompletionJul 2017
Study CompletionApr 2021
TodayJul 2026
First PostedMar 12, 2010
Enrollment StartApr 1, 2010
Primary CompletionJul 1, 2017
Study CompletionApr 1, 2021
TodayJul 2, 2026
Enrollment to primary: 7.3 yearsPosted 16.3 years ago
Interventions
pemetrexed disodiumdrug
Given IV
clinical observationother